Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections

Pharmacotherapy

Volumn 19, Issue 11 I, 1999, Pages 1261-1268

  Linden, Peter ^a   Lee, Lily ^b   Walsh, Thomas J ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Liposome Company Incorporated   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; LIPID;

ADULT; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDIASIS; CELL INVASION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MUCORMYCOSIS; MYCOSIS; NEPHROTOXICITY; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 0032700880     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.16.1261.30870     Document Type: Article

References (13)

1. Lister J. Amphotericin B lipid complex (Abelcet®) in the treatment of invasive mycoses: the North American experience. Eur J Haematol 1996;56(suppl 57):18-23.
2. Janoff AS, Perkins WR, Saletan SL, Swenson CE. Amphotericin B lipid complex (ABLC™): a molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 1993;3:451-71.
3. Swenson CE, Janoff AS. Preclinical studies with amphotericin B lipid complex. Drugs Today 1996;32:397-402.
4. Walsh TJ, Hiemenz JW, Seibel N, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-96.
5. Meunier F, Aoun M, Bitar N. Candidemia in immuno-compromised patients. Clin Infect Dis 1992;14(suppl 1): S120-5.
6. Medoff G, Dismukes WE, Meade RH III, Moses JM. A new therapeutic approach to Candida infections. Arch Intern Med 1972;130:241-5.
7. Solomkin JS, Flohr A, Simmons RL. Candida infections in surgical patients. Ann Surg 1982;195:177-85.
8. Bryce EA, Roberts FJ, Sekhon AS, Coldman AJ. Yeast in blood cultures: evaluation of factors influencing outcome. Diagn Microbiol Infect Dis 1997;15:233-7.
9. Nguyen MH, Peacock JE, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995; 155:2429-35.
10. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, WC Dunagan. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15:414-21.
11. Edwards JE Jr, Bodey GP, Bowden RA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997;25:43-59.
12. Sharkey PK, Lipke R, Renteria A, et al. Amphotericin B lipid complex (ABLC) in treatment (Rx) of coccidioidomycosis (C). In: Abstracts of the 31st interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 29-October 2, 1991. Washington DC: American Society for Microbiology, 1991.
13. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin 6 in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-21.